CCN3 and myeloid sarcoma: Despite comparable systemic levels, CCN3 was significantly upregulated in PBMCs and T cells of MS patients and almost absent in control samples, suggesting that cellular sources of CCN3 may vary as a result of MS but overall levels are not altered.